Detailed Results From Biogen Idec, Inc. (Massachusetts) And AbbVie’s Pivotal Phase 3 Decide Study Further Define The Efficacy And Safety Profile Of ZINBRYTA™ (Daclizumab High-Yield Process)

CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX® (interferon beta-1a).

Help employers find you! Check out all the jobs and post your resume.